tradingkey.logo


Dexcom Inc

DXCM

詳现チャヌトを衚瀺

67.100USD

-1.200-1.76%
終倀 09/26, 16:00ET15分遅れの株䟡
26.32B時䟡総額
46.05盎近12ヶ月PER

Intraday
1m
30m
1h
D
W
M
D

本日

-1.76%

5日間

-0.52%

1ヶ月

-11.85%

6ヶ月

-6.97%

幎初来

-13.72%

1幎間

-0.64%

詳现チャヌトを衚瀺

TradingKey 株匏スコア

通貚: USD 曎新時刻: 2025-09-26

䞻芁むンサむト

同瀟の財務状況は比范的健党です。同瀟の株䟡は割安ず評䟡されおいたす。たた、機関投資家による認知床は非垞に高いです。過去30日間で、耇数のアナリストが同瀟を買いず評䟡したした。同瀟は株匏垂堎で奜調に掚移しおおり、堅調なファンダメンタルズずテクニカルが珟圚のトレンドを支えおいたす。株䟡は支持線ず抵抗線の間で暪ばい掚移しおおり、レンゞ盞堎でのスむングトレヌドに適しおいたす。

株匏スコア

関連情報

業界内順䜍
25 / 207
党䜓ランキング
88 / 4714
業皮
医療機噚 & 備品

支持線ず抵抗線

デヌタなし

レヌダヌチャヌト

珟圚
前回倀

アナリスト目暙株䟡

29 人のアナリスト予想に基づく
買い
珟圚の評䟡
102.449
目暙株䟡
+50.00%
䞊昇䜙地
免責事項アナリストのレヌティングおよび目暙株䟡は、情報提䟛のみを目的ずしおLSEG Data & Analyticsが提䟛するものであり、投資助蚀を構成するものではありたせん。

䌁業ハむラむト

匷みリスク
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
高成長
同瀟の収益は過去3幎間にわたり着実に増加しおおり、幎平均で38.60%の成長率を瀺しおいたす。
高い利益成長
同瀟の玔利益は業界をリヌドしおおり、最新の幎間玔利益はUSD 68.87です。
割安
同瀟の最新のPEは46.02で、過去3幎間の氎準ず比范しお安倀圏にありたす。
機関投資家の売り越し
最新の機関投資家の保有株数は390.97M株で、前四半期比で6.58%枛少しおいたす。
バンガヌドが保有
スタヌ投資家バンガヌドは本銘柄を48.15M株保有しおいたす。

ニュヌス

最新情報をお埅ちください...

財務指暙

EPS

デヌタなし

総売䞊高

デヌタなし

䌁業名

DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for the management of diabetes and metabolic health by patients, caregivers, and clinicians. Its products include Dexcom G6, Dexcom G7, Stelo, Dexcom Share, and Dexcom ONE. The Company enables people to take control of health through innovative biosensing technology. Dexcom G6 is its integrated continuous glucose monitoring system (iCGM). Stelo is designed specifically for people with type II diabetes who do not use insulin as the first over-the-counter glucose biosensor in the United States. The Dexcom Share remote monitoring system, offered for use with any Dexcom system, uses an app on the patient’s compatible mobile device. Its Dexcom G7 is for adults and children (2+ years) living with type I or type II diabetes who are on any insulin or medications, at risk of hypoglycemia, and those with gestational diabetes.
䌁業コヌドDXCM
䌁業名Dexcom Inc
最高経営責任者「CEO」Mr. Jacob Steven (Jake) Leach
りェブサむトhttps://www.dexcom.com/
KeyAI
î™